InvestmentAug 12, 2026, 09:47 PM
Outlook Therapeutics Prices Public Offering at $0.99/Share
AI Summary
Outlook Therapeutics, Inc. announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants. The combined public offering price is $0.99 per share and warrant, with warrants exercisable at $1.10 per share. The company expects to raise approximately $55.0 million in gross proceeds, which will be used to support the commercial launch of LYTENAVA™ in the United States, as well as for working capital and general corporate purposes. The offering is anticipated to close on August 14, 2026.
Key Highlights
- Outlook Therapeutics priced an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants.
- The combined public offering price for each share and warrant is $0.99.
- Warrants have an exercise price of $1.10 per share and expire in five years.
- Underwriters have a 30-day option to purchase up to 8,333,333 additional shares and/or warrants.
- The offering is expected to generate approximately $55.0 million in gross proceeds.
- Net proceeds will support the commercial launch of LYTENAVA™ in the U.S. and for general corporate purposes.
- The offering is expected to close on August 14, 2026.
Price Impact
More from OTLK